These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31444140)

  • 21. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure.
    Castro P; Vukasovic JL; Chiong M; Díaz-Araya G; Alcaino H; Copaja M; Valenzuela R; Greig D; Pérez O; Corbalan R; Lavandero S
    Eur J Heart Fail; 2005 Oct; 7(6):1033-9. PubMed ID: 16227141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
    Riccioni G; Masciocco L; Benvenuto A; Saracino P; De Viti D; Massari F; Meliota G; Buta F; Speziale G
    Pharmacology; 2013; 92(5-6):276-80. PubMed ID: 24296869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In heart failure, all beta-blockers are not necessarily equal.
    Tang WH; Militello M; Francis GS
    Cleve Clin J Med; 2003 Dec; 70(12):1081-7. PubMed ID: 14686687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of beta-blockers on ventilation efficiency in heart failure.
    Agostoni P; Apostolo A; Cattadori G; Salvioni E; Berna G; Antonioli L; Vignati C; Schina M; Sciomer S; Bussotti M; Palermo P; Fiorentini C; Contini M
    Am Heart J; 2010 Jun; 159(6):1067-73. PubMed ID: 20569721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
    Marazzi G; Iellamo F; Volterrani M; Caminiti G; Madonna M; Arisi G; Massaro R; Righi D; Rosano GM
    Am J Cardiol; 2011 Jan; 107(2):215-9. PubMed ID: 21129714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
    Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
    Sessa M; Mascolo A; Mortensen RN; Andersen MP; Rosano GMC; Capuano A; Rossi F; Gislason G; Enghusen-Poulsen H; Torp-Pedersen C
    Eur J Heart Fail; 2018 Mar; 20(3):548-556. PubMed ID: 29159953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol.
    Dalla Libera L; Ravara B; Gobbo V; Danieli Betto D; Germinario E; Angelini A; Vescovo G
    J Mol Cell Cardiol; 2005 May; 38(5):803-7. PubMed ID: 15850574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Beta-adrenolytics in heart failure--are they all really equal?].
    Filipiak KJ; Opolski G
    Przegl Lek; 2005; 62 Suppl 2():39-42. PubMed ID: 16623117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term oral carvedilol in chronic heart failure.
    Di Lenarda A; Sabbadini G; Moretti M; Sinagra G
    Expert Opin Pharmacother; 2004 Jun; 5(6):1359-72. PubMed ID: 15163280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisoprolol in the treatment of chronic heart failure.
    de Groote P; Ennezat PV; Mouquet F
    Vasc Health Risk Manag; 2007; 3(4):431-9. PubMed ID: 17969374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
    Mortara A; La Rovere MT; Pinna GD; Maestri R; Capomolla S; Cobelli F
    J Am Coll Cardiol; 2000 Nov; 36(5):1612-8. PubMed ID: 11079666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
    Nagatomo Y; Yoshikawa T; Kohno T; Yoshizawa A; Anzai T; Meguro T; Satoh T; Ogawa S
    J Card Fail; 2007 Jun; 13(5):365-71. PubMed ID: 17602983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-blockers in heart failure. The 'new wave' of clinical trials.
    Krum H
    Drugs; 1999 Aug; 58(2):203-10. PubMed ID: 10473016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
    Galatius S; Gustafsson F; Atar D; Hildebrandt PR
    Cardiology; 2004; 102(3):160-5. PubMed ID: 15334027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.
    Kukin ML; Kalman J; Charney RH; Levy DK; Buchholz-Varley C; Ocampo ON; Eng C
    Circulation; 1999 May; 99(20):2645-51. PubMed ID: 10338457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
    Hamaad A; Lip GY; Nicholls D; MacFadyen RJ
    Cardiovasc Drugs Ther; 2007 Dec; 21(6):437-44. PubMed ID: 17896170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.